This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: iron deficiency

News from the Cardiorenal Forum 12th Annual Scientific Meeting – Improving treatments in cardiorenal patients

March 2018

News from the Cardiorenal Forum 12th Annual Scientific Meeting – Improving treatments in cardiorenal patients

Fazlullah Wardak and Rosie Kalsi

Abstract

Do new diabetes drugs protect the heart and kidney? The day’s keynote session was given by Professor Johannes Mann (Friedrich Alexander University of Erlangen, Germany). Diabetes management has been transformed with the introduction of newer agents with the promise of cardiovascular and renal protection. The sodium glucose co-transporter-2 (SGLT-2) inhibitors are known to reduce the hyperfiltration, which occurs in early diabetic nephropathy. Glucagon-like peptide 1 (GLP-1) receptor agonists are incretin mimetics, which have several benefits for diabetes management. The mechanisms by which GLP-1 agonist therapy may reduce blood pressur

| Full text

October 2017

ESC 2017: Evidence supports treatment of iron deficiency in heart failure

BJC staff

Abstract

This topic was addressed by Dr Carolyn Lam (National Heart Centre, Singapore) during a Vifor satellite symposium. Iron deficiency is frequently defined as a serum ferritin <100 μg/L (or 100–299 ng/ml, if transferrin saturation [TSAT] <20%); the usual iron deficit in a 35–70 kg heart failure patient with a haemoglobin 10–14 g/dl is 1,000 mg. Iron deficiency is common irrespective of haemoglobin, sex, ethnicity, and even ejection fraction. In heart failure patients it adversely affects: functional status, including exercise capacity quality of life outcome Iron deficiency (but not anaemia) is associated with adverse prognosis. My

| Full text

March 2012 Br J Cardiol 2012;19:15

Correspondence: Anaemia in CHF

Mohammed Shamim Rahman, Matthew Pavitt, TP Chua

Abstract

Anaemia in chronic heart failure: what constitutes optimal investigation and treatment? Dear Sirs, We read with interest the recent supplement on anaemia in heart failure patients.1 Since the publication by Bolger et al.2 on the benefits of intravenous iron therapy in chronic heart failure (CHF), we have been screening for anaemia and iron deficiency in this cohort. We actively treat these patients based on the criteria of a haemoglobin level less than 12 g/dL, already on optimal conventional heart failure therapy, New York Heart Association (NYHA) class II symptoms or worse, and a ferritin of less than 100 μg/L. We were previously using an

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now